Mensil Max (Sildenafil Citrate)

Mensil Max, a PDE5 inhibitor, is used to manage conditions related to vascular smooth‑muscle tone.

• Erectile dysfunction: improves the ability to achieve and maintain an erection during sexual activity.
• Pulmonary arterial hypertension: reduces pulmonary arterial pressure and enhances exercise capacity in affected patients.
• Severe pulmonary hypertension in newborns: approved in certain regions for reducing pulmonary vascular resistance in neonatal patients.

• Sildenafil citrate selectively inhibits phosphodiesterase type 5 enzymes, preventing the breakdown of cyclic guanosine monophosphate (cGMP). Elevated cGMP levels lead to relaxation of smooth muscle in the corpus cavernosum and pulmonary vasculature, enhancing blood flow and facilitating erection or reducing pulmonary arterial pressure.

Sildenafil is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate pain often occurring shortly after dosing.
• Flushing: warmth and redness of the face or upper chest.
• Dyspepsia: indigestion or upset stomach.
• Nasal congestion: stuffy or runny nose.
• Visual disturbances: blurred vision or color tinge changes.
• Back pain: muscle ache, typically 12‑24 hours post‑dose.

Serious or Rare Side Effects

• Priapism: prolonged erection lasting more than four hours, requiring urgent medical attention.
• Sudden hearing loss: unexplained decrease or loss of hearing.
• Cardiovascular events: rare cases of myocardial infarction or stroke, especially in patients with pre‑existing heart disease.

Before prescribing Mensil Max, clinicians should evaluate patient risk factors and contraindications.

• Cardiovascular assessment: ensure patient can tolerate sexual activity.
• Nitrate use: avoid concurrent administration with nitrates or nitric‑oxide donors.
• Hepatic impairment: use with caution in severe liver disease.
• Alcohol consumption: limit excessive intake as it may increase side‑effects.
• Blood pressure monitoring: watch for symptomatic hypotension.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Sildenafil may interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Nitrates (e.g., nitroglycerin): risk of severe hypotension.
• Guanylate cyclase stimulators (e.g., riociguat): additive vasodilatory effect.
• Other PDE5 inhibitors: increased risk of adverse events.

Moderate Interactions (Monitor Closely)

• Alpha‑blockers: may cause additive blood pressure lowering.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase sildenafil plasma levels.
• CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce efficacy of sildenafil.
• Antihypertensives: monitor for enhanced hypotensive response.